ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Risk Factors for the Development of CMV Viremia in a Cohort of Morbidly Obese Kidney Transplant Recipients Under Low Dose Valganciclovir Prophylaxis.

J. Thielke,1 N. Jasiak,1 N. Hilal,1 S. Salah,1 E. Benedetti,2 P. West-Thielke.2

1Pharmacy Practice, Univ of IL-Chicago Medical Center, Chicago, IL
2Dept of Surgery, Univ of IL-Chicago Medical Center, Chicago, IL.

Meeting: 2016 American Transplant Congress

Abstract number: C286

Keywords: Cytomeglovirus, Kidney transplantation, Obesity, Risk factors

Session Information

Date: Monday, June 13, 2016

Session Name: Poster Session C: Viruses and SOT

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Halls C&D

Related Abstracts
  • Incidence of CMV Viremia in Obese and Morbidly Obese Kidney Transplants Under a Low Dose Valganciclovir Prophylaxis Protocol
  • Do Morbidly Obese Patients Have an Increased Risk of Infection Post-Kidney Transplant?

Background: The rate of Cytomegalovirus infections in kidney transplant recipients drastically diminished with the advent of oral ganciclovir and subsequently valganciclovir. However it continues to be one of the most prevalent and concerning opportunistic infections in the transplant recipient. Various dosing strategies have been studied and reported over the last 15 years. We previously reported an increased prevalence of CMV viremia in obese patients versus non-obese. We aimed to look at various risk factors for development of CMV in this population.

Methods: From Jan 2009 to April 2014 we identified 189 kidney transplants in patients with a BMI>35. These patients received our standard prophylaxis of valganciclovir 450mg daily (adjusted for GFR based on MDRD) started by POD7 and continued for 6 months after transplant for all patients except donor neg/recipient neg serostatus. CMV PCR was checked at 3, 6, 9 and 12 months after transplant or at any time of concern for CMV infection.

Results: 144 patients had full data to evaluate during the time period. The overall incidence of CMV viremia was 11.1%. There was no difference in incidence of CMV viremia based on tacrolimus dosing requirement, with the thought this would represent poor absorbers. Other variables are broken down in Table 1. The average GFR (MDRD) in the patient's who developed CMV was only 47.1ml/min/m2. The 1 year pt and graft survival in patients who developed CMV was still 100%.

Variable (n=144) CMV Viremia (n=16) p value
 Race    
  AA (85) 15.3%  
  C and H (57) 3.5% 0.02 vs AA
     
 Induction    
  Basiliximab (39) 5.1%  
  Thymoglobulin (100) 13% 0.23
     
 Peri-op pheresis (33) 24%  
 No pheresis (107) 6.5% 0.008
     
 CNI    
  CSA (13) 7.7%  
  Tac (129) 11.6% ns
     
 Serology    
  neg/neg 0%  
  neg/pos 5.9%  
  pos/neg 30.7%  
  pos/pos 12.9%  

Conclusion: In a population of morbidly obese kidney transplant patients, AA race and use of peri-operative plasmapheresis were identified as risk factors for the development of CMV viremia. Further evaluation of adjustment of valganciclovir dosing for GFR and subsequent development of CMV viremia is underway.

CITATION INFORMATION: Thielke J, Jasiak N, Hilal N, Salah S, Benedetti E, West-Thielke P. Risk Factors for the Development of CMV Viremia in a Cohort of Morbidly Obese Kidney Transplant Recipients Under Low Dose Valganciclovir Prophylaxis. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Thielke J, Jasiak N, Hilal N, Salah S, Benedetti E, West-Thielke P. Risk Factors for the Development of CMV Viremia in a Cohort of Morbidly Obese Kidney Transplant Recipients Under Low Dose Valganciclovir Prophylaxis. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/risk-factors-for-the-development-of-cmv-viremia-in-a-cohort-of-morbidly-obese-kidney-transplant-recipients-under-low-dose-valganciclovir-prophylaxis/. Accessed February 28, 2021.

« Back to 2016 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.